Bioxytran, Inc.
BIXT
$0.02
$0.005.42%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -76.63% | 182.11% | |||
| Depreciation & Amortization | 166.67% | -27.59% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -65.88% | 217.14% | |||
| Operating Income | 65.88% | -217.14% | |||
| Income Before Tax | 70.04% | -296.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 70.04% | -296.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 70.04% | -296.21% | |||
| EBIT | 65.88% | -217.14% | |||
| EBITDA | 66.14% | -218.31% | |||
| EPS Basic | 70.65% | -253.85% | |||
| Normalized Basic EPS | 70.43% | -180.49% | |||
| EPS Diluted | 70.65% | -253.85% | |||
| Normalized Diluted EPS | 70.43% | -180.49% | |||
| Average Basic Shares Outstanding | 1.85% | 11.67% | |||
| Average Diluted Shares Outstanding | 1.85% | 11.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||